Survey of Pharmacoeconomic Assessment Activity in Eleven Countries:
Policy-makers responsible for publicly-funded drug programmes face continual pressures between the demand to accommodate a steady stream of new and more effective drugs and the ongoing requirement to control costs. In the face of these pressures, a growing number of OECD countries are applying '...
Gespeichert in:
| Beteilige Person: | |
|---|---|
| Weitere beteiligte Personen: | , |
| Format: | Elektronisch E-Book |
| Sprache: | Englisch |
| Veröffentlicht: |
Paris
OECD Publishing
2003
|
| Schriftenreihe: | OECD Health Working Papers
|
| Schlagwörter: | |
| Links: | https://doi.org/10.1787/678644556018 |
| Zusammenfassung: | Policy-makers responsible for publicly-funded drug programmes face continual pressures between the demand to accommodate a steady stream of new and more effective drugs and the ongoing requirement to control costs. In the face of these pressures, a growing number of OECD countries are applying 'pharmacoeconomic assessment' (health technology assessment for drugs) - to new drugs to guide decisions about accepting such products for reimbursement under their public programme, or to inform negotiations about pricing. This paper provides an analytical overview of the developing practice of pharmacoeconomic assessment in eleven OECD countries. It looks at the objectives of the activity, some of its processes and some of its impacts. It does this by drawing on a literature review and on an exploratory survey of the activities of pharmacoeconomic agencies in the eleven countries. It also reviews briefly the state of pharmacoeconomic assessment in the United States. The main conclusions are as ... |
| Umfang: | 1 Online-Ressource (44 Seiten) 21 x 29.7cm |
| DOI: | 10.1787/678644556018 |
Internformat
MARC
| LEADER | 00000nam a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV047933157 | ||
| 003 | DE-604 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 220413s2003 xx o|||| 00||| eng d | ||
| 024 | 7 | |a 10.1787/678644556018 |2 doi | |
| 035 | |a (ZDB-13-SOC)061297550 | ||
| 035 | |a (OCoLC)1312710263 | ||
| 035 | |a (DE-599)BVBBV047933157 | ||
| 040 | |a DE-604 |b ger |e aacr | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-384 |a DE-91 |a DE-473 |a DE-824 |a DE-29 |a DE-739 |a DE-355 |a DE-20 |a DE-1028 |a DE-1049 |a DE-188 |a DE-521 |a DE-861 |a DE-898 |a DE-92 |a DE-573 |a DE-19 | ||
| 100 | 1 | |a Dickson, Michael |e Verfasser |4 aut | |
| 245 | 1 | 0 | |a Survey of Pharmacoeconomic Assessment Activity in Eleven Countries |c Michael Dickson, Jeremy Hurst and Stephane Jacobzone |
| 264 | 1 | |a Paris |b OECD Publishing |c 2003 | |
| 300 | |a 1 Online-Ressource (44 Seiten) |c 21 x 29.7cm | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 490 | 0 | |a OECD Health Working Papers | |
| 520 | |a Policy-makers responsible for publicly-funded drug programmes face continual pressures between the demand to accommodate a steady stream of new and more effective drugs and the ongoing requirement to control costs. In the face of these pressures, a growing number of OECD countries are applying 'pharmacoeconomic assessment' (health technology assessment for drugs) - to new drugs to guide decisions about accepting such products for reimbursement under their public programme, or to inform negotiations about pricing. This paper provides an analytical overview of the developing practice of pharmacoeconomic assessment in eleven OECD countries. It looks at the objectives of the activity, some of its processes and some of its impacts. It does this by drawing on a literature review and on an exploratory survey of the activities of pharmacoeconomic agencies in the eleven countries. It also reviews briefly the state of pharmacoeconomic assessment in the United States. The main conclusions are as ... | ||
| 650 | 4 | |a Social Issues/Migration/Health | |
| 700 | 1 | |a Hurst, Jeremy |4 ctb | |
| 700 | 1 | |a Jacobzone, Stephane |4 ctb | |
| 856 | 4 | 0 | |u https://doi.org/10.1787/678644556018 |x Verlag |z kostenfrei |3 Volltext |
| 912 | |a ZDB-13-SOC | ||
| 943 | 1 | |a oai:aleph.bib-bvb.de:BVB01-033314651 | |
Datensatz im Suchindex
| DE-BY-OTHR_katkey | 6532516 |
|---|---|
| DE-BY-TUM_katkey | 2629518 |
| _version_ | 1831257604199809025 |
| adam_text | |
| any_adam_object | |
| author | Dickson, Michael |
| author2 | Hurst, Jeremy Jacobzone, Stephane |
| author2_role | ctb ctb |
| author2_variant | j h jh s j sj |
| author_facet | Dickson, Michael Hurst, Jeremy Jacobzone, Stephane |
| author_role | aut |
| author_sort | Dickson, Michael |
| author_variant | m d md |
| building | Verbundindex |
| bvnumber | BV047933157 |
| collection | ZDB-13-SOC |
| ctrlnum | (ZDB-13-SOC)061297550 (OCoLC)1312710263 (DE-599)BVBBV047933157 |
| discipline | Wirtschaftswissenschaften |
| doi_str_mv | 10.1787/678644556018 |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>00000nam a2200000zc 4500</leader><controlfield tag="001">BV047933157</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">220413s2003 xx o|||| 00||| eng d</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1787/678644556018</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-13-SOC)061297550</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1312710263</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV047933157</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">aacr</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-384</subfield><subfield code="a">DE-91</subfield><subfield code="a">DE-473</subfield><subfield code="a">DE-824</subfield><subfield code="a">DE-29</subfield><subfield code="a">DE-739</subfield><subfield code="a">DE-355</subfield><subfield code="a">DE-20</subfield><subfield code="a">DE-1028</subfield><subfield code="a">DE-1049</subfield><subfield code="a">DE-188</subfield><subfield code="a">DE-521</subfield><subfield code="a">DE-861</subfield><subfield code="a">DE-898</subfield><subfield code="a">DE-92</subfield><subfield code="a">DE-573</subfield><subfield code="a">DE-19</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Dickson, Michael</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Survey of Pharmacoeconomic Assessment Activity in Eleven Countries</subfield><subfield code="c">Michael Dickson, Jeremy Hurst and Stephane Jacobzone</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Paris</subfield><subfield code="b">OECD Publishing</subfield><subfield code="c">2003</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (44 Seiten)</subfield><subfield code="c">21 x 29.7cm</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">OECD Health Working Papers</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Policy-makers responsible for publicly-funded drug programmes face continual pressures between the demand to accommodate a steady stream of new and more effective drugs and the ongoing requirement to control costs. In the face of these pressures, a growing number of OECD countries are applying 'pharmacoeconomic assessment' (health technology assessment for drugs) - to new drugs to guide decisions about accepting such products for reimbursement under their public programme, or to inform negotiations about pricing. This paper provides an analytical overview of the developing practice of pharmacoeconomic assessment in eleven OECD countries. It looks at the objectives of the activity, some of its processes and some of its impacts. It does this by drawing on a literature review and on an exploratory survey of the activities of pharmacoeconomic agencies in the eleven countries. It also reviews briefly the state of pharmacoeconomic assessment in the United States. The main conclusions are as ...</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Social Issues/Migration/Health</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hurst, Jeremy</subfield><subfield code="4">ctb</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Jacobzone, Stephane</subfield><subfield code="4">ctb</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1787/678644556018</subfield><subfield code="x">Verlag</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-13-SOC</subfield></datafield><datafield tag="943" ind1="1" ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-033314651</subfield></datafield></record></collection> |
| id | DE-604.BV047933157 |
| illustrated | Not Illustrated |
| indexdate | 2025-01-11T15:45:40Z |
| institution | BVB |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-033314651 |
| oclc_num | 1312710263 |
| open_access_boolean | 1 |
| owner | DE-384 DE-91 DE-BY-TUM DE-473 DE-BY-UBG DE-824 DE-29 DE-739 DE-355 DE-BY-UBR DE-20 DE-1028 DE-1049 DE-188 DE-521 DE-861 DE-898 DE-BY-UBR DE-92 DE-573 DE-19 DE-BY-UBM |
| owner_facet | DE-384 DE-91 DE-BY-TUM DE-473 DE-BY-UBG DE-824 DE-29 DE-739 DE-355 DE-BY-UBR DE-20 DE-1028 DE-1049 DE-188 DE-521 DE-861 DE-898 DE-BY-UBR DE-92 DE-573 DE-19 DE-BY-UBM |
| physical | 1 Online-Ressource (44 Seiten) 21 x 29.7cm |
| psigel | ZDB-13-SOC |
| publishDate | 2003 |
| publishDateSearch | 2003 |
| publishDateSort | 2003 |
| publisher | OECD Publishing |
| record_format | marc |
| series2 | OECD Health Working Papers |
| spellingShingle | Dickson, Michael Survey of Pharmacoeconomic Assessment Activity in Eleven Countries Social Issues/Migration/Health |
| title | Survey of Pharmacoeconomic Assessment Activity in Eleven Countries |
| title_auth | Survey of Pharmacoeconomic Assessment Activity in Eleven Countries |
| title_exact_search | Survey of Pharmacoeconomic Assessment Activity in Eleven Countries |
| title_full | Survey of Pharmacoeconomic Assessment Activity in Eleven Countries Michael Dickson, Jeremy Hurst and Stephane Jacobzone |
| title_fullStr | Survey of Pharmacoeconomic Assessment Activity in Eleven Countries Michael Dickson, Jeremy Hurst and Stephane Jacobzone |
| title_full_unstemmed | Survey of Pharmacoeconomic Assessment Activity in Eleven Countries Michael Dickson, Jeremy Hurst and Stephane Jacobzone |
| title_short | Survey of Pharmacoeconomic Assessment Activity in Eleven Countries |
| title_sort | survey of pharmacoeconomic assessment activity in eleven countries |
| topic | Social Issues/Migration/Health |
| topic_facet | Social Issues/Migration/Health |
| url | https://doi.org/10.1787/678644556018 |
| work_keys_str_mv | AT dicksonmichael surveyofpharmacoeconomicassessmentactivityinelevencountries AT hurstjeremy surveyofpharmacoeconomicassessmentactivityinelevencountries AT jacobzonestephane surveyofpharmacoeconomicassessmentactivityinelevencountries |